DOI: 10.55522/jmpas.V11I3.1874 ISSN NO. 2320–7418

International peer reviewed open access journal

Journal of Medical Pharmaceutical and Allied Sciences

Journal homepage: www.jmpas.com CODEN: JMPACO

Review article

Global concern of antimicrobial effectiveness and resistance combat strategies

Swayamprabha Sahoo[1], Jatindra Nath Mohanty*[2], Tapas Ranjan Behera[3], Rajesh Kumar Lenka[4], Saurjya Ranjan Das[5]

[1]Centre of Biotechnology, SOA deemed to be University, Bhubaneswar, Odisha, India
[2]Medical Research Laboratory, IMS and Sum Hospital, SOA deemed to be University, Bhubaneswar, Odisha, India.
[3]Department of Nephrology, IMS and Sum Hospital, SOA deemed to be University, Bhubaneswar, Odisha, India.
[4]Department of Microbiology, IMS and Sum Hospital, SOA deemed to be University, Bhubaneswar, Odisha, India.
[5]Department of Anatomy, IMS and Sum Hospital, SOA deemed to be University, Bhubaneswar, Odisha, India.

ABSTRACT

Antibiotic resistance is a major threat that associated with deficient in discovery of new antibiotics. Although some countries have been capable to contain resistance, but in most countries antibiotic resistant bacteria prolong to rise with antibiotic consumption in both humans as well as animals. For all decision makers worldwide, the antibiotic resistance is a global issue and a major concern. Some proceedings have been carried out in the last 15 years, in particular by the World Health Organization, the Centre for Diseases Control and Prevention and the European Centre for Diseases Prevention and Control. However those accomplishments were incomplete and poorly implemented, without proper coordination. Our aim in this review is to understand the cause and effectiveness of antimicrobial resistance by putting some lights from evolution of antimicrobial resistance. Like bacteria, different microorganisms have consistently developed so they can oppose the new medications that medication has used to battle them. Obstruction has progressively become an issue as of late on the grounds that the speed at which we are finding novel anti-microbial has eased back radically, while anti-microbial use is rising. Also, it's difficult an issue bound to microorganisms, however all organisms that can possibly transform and deliver our medications insufficient.

Keywords: Bacteria, Combat Strategies, AMR, Global Concern, Evolution.

Received - 09-09-2021, Accepted- 30-04-2022

Correspondence: Dr. Jatindra Nath Mohanty*✉jatindranathmohanty@soa.ac.in, **Orcid Id:** https://orcid.org/0000-0001-9228-8395

Medical Research Laboratory, IMS and Sum Hospital, SOA deemed to be University, Bhubaneswar, Odisha, India

INTRODUCTION

The variety in the AMR issues of individual nations is connected to tremendous contrasts in how intensely they utilize antimicrobial medications. Worldwide utilization of antibiotics in human medication rose by almost 40% somewhere in the range of 2000 and 2010, yet these figure veils examples of declining use in certain nations and fast development in others. The BRIC nations in addition to South Africa represented 3/4 of this development, while yearly per-individual utilization of antibiotics differs by in excess of a factor of 10 across all center and major league salary nations [1].

The occurrence of multidrug-resistant Gram-negative microorganisms causes nosocomial infections or more popularly known as health-care associated infections (HAIs) and hospital acquired infections, is a rising issue around the world. There has as of late been a gigantic increment in infection brought about by multidrug resistance Gram-negative microorganisms, particularly *Acinetobacter baumannii*, *Klebsiella pneumonia* and *Pseudomonas aeruginosa*.

According to numerous reports, these species Polymyxins (A to E) are frequently the key accessible active antibiotics agents [2,3]. Most precisely, polymyxins E called colistin, fill in as the last elective antibiotics [4]. Colistin got accessible for scientific use during the 1960s, however, it was supplanted during the periods of 1970s with different antibiotics inferable from its lethality [2,4]. Utilization of Colistin was limited after the possibly fewer toxic aminoglycosides and some other anti-pseudomonal agents were become obtainable [5]. During the early 1980s, colistin and polymyxin B's intravenous formulations were significantly restricted in almost all parts of the globe because of the increasing report of nephrotoxicity [6]. Later, the arterial use of colistin was commonly controlled in the last two decades for dealing with the lung infections due to the MDR (Multiple Drug Resistance), GNB with cystic fibrosis patients [7]. From that time, polymyxins (colistin) were used as a valuable therapeutic option because of the advent of bacteria unaffected to maximum groups of commercially handy antibiotics and also the

scarcity of novel agents that can act against the gram-negative microbes. In another hand, rates of colistin resistance have been comparatively less, probably due to the infrequent usage, another cause may more development of colistin-resistant bacteria infection by its use [7,8]. Because of the scarcity of novel antibiotics which can act against GNB will be obtainable within the next nine to eleven years, so there is a critical necessity to optimize the use of CMS/colistin. As with all infectious diseases, the speed and volume of intercontinental travel today creates new opportunities for antimicrobial-resistant pathogens to be spread internationally. Such mixing of diverse microbes, particularly bacteria, provides them with opportunities to share their genetic material with each other, which creating new resistant strains at an unprecedented pace. No country can therefore successfully tackle AMR by acting in isolation**.** This study aim is to enable the researchers to get some valuable strategies from evolution of AMR to tackle in different circumstances.

Evolution of antibiotic resistance

The first effective antimicrobial specialist, sulfonamide, was presented in 1937. Inside 2 years, sulfonamide resistance was accounted for and similar AR systems are still clinically present over 70 years later [9]. One valuable method of understanding the fundamental components of AR is through the slug and target idea, whereby the locales of medication movement (the objective) can be changed by enzymatic adjustment, changed by genomic transformations, and skirted metabolically (eg, sulfonamide resistance); the anti-microbial (the shot) can go through enzymatic inactivation and debasement (eg, beta-lactamases), diminished admittance into the phone (eg, porin), and expanded expulsion from the phone (eg, efflux pumps) [9,10] . There is arising proof that obstruction instruments in Mycobacterium tuberculosis (MTb), one of the most seasoned and most far and wide human microorganisms, are initiated by changes brought about by sub-inhibitory convergences of antibiotics [11].

Patients with MTb who recently got quinolone anti-infection agents created protection from both this anti-infection class just as to first-line against MTb drugs [12]. These information show a solid and direct connection between the utilization of anti-microbials and resistance. One illustration of contemporary development in obstruction instruments is *Salmonella Typhi*. Prior to the antimicrobial time, typhoid fever claimed a 20% death rate, which was fundamentally decreased with the presentation of successful treatment. Fluoroquinolones turned into the specialists of decision during the 1990s, yet 1 genealogy of Salmonella with decreased powerlessness has broadly disseminated [13], unfortunately endeavors to foster novel treatments against *Salmonella Typhi* are minimal [14]. Thus, we are nearly inescapable resistance with few compelling choices for typhoid fever, raising the chance of a re-visitation of the PR antibiotic period for this disease [15,16].

Antibiotics as a drug

Due to the lack of new class of antibiotic and upswing of multidrug resistance gram negative microbes to fight against them, have urge the recovery of old group of cationic and cyclic polypeptide antibiotic “Polymyxin”. Polymyxin B and Polymyxin E are mostly appropriate for clinical utilization. During the last couple of years, the reintroduction of polymyxins is the greater part that associated with colistin. The polymyxins class of antibiotics is dynamic against some selected GNB, including *P. aeruginosa*, *A. baumannii*, *K. pneumonia*, and *Enterobacter* species [17]. Yet the parental utilization of these drugs was relinquished ∼20 years prior in many nations for the treatment of patients with cystic fibrosis, neurotoxicity, normal and genuine nephrotoxicity. Polymyxins, a mixture of 5 polypeptide antibiotics comprise of Polymyxin A, B, C, D and E was first introduced in 1947.

It was investigated that the patient who got Polymyxins intravenously for the treatment of Bacteremia, UTI and pneumonia infected by *P. aeruginosa* and *A. baumannii* have shown to be less harmful and worthy viable [16]. For treatment of topical otic and ophthalmic solution, Polymyxin B and polymyxin E have been extensively used from many years. [18]. In 1949 colistin was found ribosomal Ly by combining with Bacillus polymyxa subspecies. Polymyxin E was first utilized therapeutically in Japan and Europe in the year 1950 along with in the year 1959 it was utilized in the United State in the form of colistimethatesodium [11]. Along with 1980 colistin was used intravenously and restricted during the past 2 decades due to multidrug resistance microbes for the treatment of lung infection of cystic fibrosis patient. Bacterial resistance was developed against most classes of commercially available antibiotics and the absence of new antimicrobial agent against GNB has developed the reconsideration of polymyxin as an essential therapeutic choice [19].

Colistin is the last line of antibiotics treated against multidrug resistance Gram negative bacterial infection caused by ESKAPE pathogens. Currently the therapeutic option against carbapenem resistance gram negative bacilli creates a great problem in clinical practices. Penicillin a beta-lactam antibiotic was discovered by Scottish researcher and Nobel laureate Alexander Fleming has been utilized to healing the infectious disease caused by microorganisms, Moreover, the increasing rate of resistance of drugs is known as 'superbugs' that give the new challenges for scientists.

The antibiotic resistance is not only a sectional issue, it's a worldwide issue. Normally bacteria are resistance to antibiotics, it limits the treatment option that raises the mortality and morbidity and increases the hazard of antibiotics related adverse situation. The resistance of antibiotics is termed as the ability of a microorganism to

withstand the impacts of antibiotics. It is a sort of medication resistance. Antibiotic resistance develops using natural selection via random mutation; however, likewise it could be built by applying a developmental weight on a population. When such a gene is developed, the microorganisms would then be able to transfer the hereditary information horizontally. (Between the individuals) by plasmid exchange. If a bacterium transmits a few resistance genes, it is called multidrug resistance or, a superbug. So Colistin has been re-surveyed as a fundamentally significant antimicrobial in people because of its efficiency against multidrug resistance Gram negative bacteria, specifically *Pseudomonas aeruginosa*, *Acinetobacter baumannii* and *Klebsiella pneumoniae*. In the 21st century, Colistin is probable the last combat antibiotic against gram negative multidrug-resistance pathogens [4]. Prevention is superior to cure. The nearest look at antibiotic resistance will help the researchers to develop new antibiotics. Keeping away from wrong use and abuse of antibiotics would hinder the spread of resistant microbes. As microorganisms dependably advance and can grow increasingly more resistant, new antibiotics are expected to fight against them. World Health Organization prescribes rules and some worldwide systems are overcome these major issues.

Natural antibiotic resistance mechanisms

In *P. mirabilis* and *S. marcesens* the resistance to polymyxins occurs naturally by changing the LPS by cationic replacement. In these species, the resistance mechanism is correlated with the arnBCADTEF operon and the expression of the eptB gene. Thus, this operon and gene addition to 4-amino-4-deoxy-L-arabinose (L-Ara4N) and phosphor-ethanolamine (pEtN) cationic groups occurs to the LPS respectively was shown that P. mirabilis, LPS comprises L-Ara4N, and this bacterium's genome contains the eptC gene controlled by PETN [20,21] modification. In *P. mirabilis*, putative loci include the sap operon encoding a transportation protein, the ATPase gene, and the O-acetyltransferase gene involved in the transmission of biosynthesis or amino arabinose. It has also been discovered that the presence of rppA / rppB TCS plays a role in triggering the arnBCADTEF operon. Likewise, the intrinsic colistin resistance in *S. marcescens* is responsible for this operon, as arn B and arn C mutants have been shown to minimize colistin insusceptibility (minimum inhibitory concentration [MIC] of 2.048 to 2 μg /mL) compared to wild type. This improvement in the LPS and the rise in its charge contribute to a decrease in colistin's affinity to bind to LPS. Therefore, latent resistance has arisen in these species [21,22].

Problem statement

With augmented wealth and the wider availability of antibiotics in developing countries we are observing major increases in worldwide antibiotic use at a time when fiscal restraint is being exerted in resource-rich countries. In an ecological context the parallels with man-made climate change are uncanny. There are still large areas of the world where there are shortages of antibiotics or poor access to them and consequent high mortality from pneumonia [23]. This growing demand in resource-poor countries is met by cheap options, increasingly produced in these countries [24].

Figure 1: Current issues and feasible treatment of AMR



We are hence set for additional significant expansions in antimicrobial utilization, and along these lines obstruction, around the world. Besides, as the current (and most recent) yield of wide range β-lactam anti-toxins and quinolones fall off patent, expanded utilization will be additionally determined by an expanded number of (ever less expensive) brands. This expanded utilization will be in the space of most unfortunate cleanliness and sterilization, further catapulting the rise and transmission of the up and coming age of

protections so all around depicted in the join articles by French and Walsh. Illicit, low quality and frequently honestly fake medications additionally represent an expanding issue, especially with web buys.

Moreover, a horrible twisting of environmental change, dry spells and floods will additionally irritate the circumstance by leaving weak people under swarmed and unsanitary conditions. Ever-increasing quick relaxation travel and movement will prompt ever quicker worldwide spread of these new obstruction determinants [25]. Ultimately, the dramatic decrease in new classes of anti-toxins in the course of recent many years, and a vacant pipeline of new classes being developed, prompts the inescapable end that not a single cure is to be seen and things can just deteriorate [26,27]. In spite of this, reports reliably propose a decrease in irresistible illnesses as reasons for unexpected passing and give a misguided feeling that all is well and good to leaders.

Problem of Post antibiotic era

In spite of the fact that recognizing and growing new medications is a possible answer for the AR issue, this is an expensive and confounded undertaking. Subsequently, elective systems are essential, especially in low-pay nations. A significant and successful approach to restrict the spread of AR is to lessen the utilization of anti-toxins. In 2004, Bergman and colleagues [28] showed that local macrolide use was firmly connected with erythromycin opposition in Streptococcus pyogenes. Lessening anti-toxins is one of the for reducing antibiotics is one of the central tenets of antibiotic stewardship, now universally recognized as beneficial [29]. For example, a stewardship program from a Swedish university hospital decreased antibiotic usage by 27% without any negative impact on patient outcomes, primarily by limiting broad-spectrum agents [30]. However, decreasing anti-microbial utilization alone isn't a panacea for halting AR, which requires a diverse methodology. As of late, the World Alliance against Antibiotic Resistance set forward a statement that included 10 recommendations for handling AR [31]. Several of them (eg, more quick analytic tests, anti-microbial stewardship, and observation organizations) were not groundbreaking thoughts but rather in any case are generally perceived as helpful. In this manner, the worth of the revelation is that it convincingly and definitively passes on the suggestions through a worldwide viewpoint. One important concept in the document that deserves emphasis is the pressing need for a national surveillance mechanism in developed country.

Currently there are several public databases and global surveillance projects, including Antimicrobial Resistance: Global Report on Surveillance, from the WHO; the European Antimicrobial Resistance Interactive Database; the Surveillance Network database in the United States and Australia; and the global Study for Monitoring Antimicrobial Resistance Trends. In 2002, this last study began to monitor in vitro resistance of GNB in intra-abdominal infections and more recently has focused on resistance to carbapenem and ESBLs [32]. What remains lacking is an integrated database that links data on resistance in environmental bacteria to existing databases on AR bacteria and AR genes in clinical, veterinary, and food-associated products [21].

CONCLUSION

Possible future strategic

AMR is a critical issue on the ascent over the globe. As we observed, expanding the occurrence of infectivity's due to carbapenem resistance microbes be getting hard to treat, because of the restricted accessibility of therapeutic agents [33]. Colistin is commonly favored for treatingcases brought about by pan-drug-resistant strains basically the carbapenems producers despite its toxicity. Other than colistin, different other anti-microbials in the polymyxin groups are dynamic against those Gram-negative microbes that include Klebsiella species, Pseudomonas aeruginosa, Acinetobacter species, and Enterobacter species [4]. Colistin is a viable suitable anti-microbial for the treatment of most multidrug-resistant Gram-negative microscopic organisms. It is used by and by as a last-line drug for diseases in light of serious Gram-negative microorganisms followed by an extension in resistance among Gram-negative bacteria [34]. Different therapeutic management is considered to overcome the administration of last-line antibiotics. During the most recent couple of years, it's also observed from Osaka University in science news which was published in the journal of antimicrobial Chemotherapy, that nightmare bacteria exhibiting resistance to colistin which were the last resort therapy against MDR [35]. Colistin obstruction is viewed as a significant issue because of an absence of particular antibiotics. Many known ways of investigation for AMR have fizzled; we have to come back to the planning phase and search for new ones. One important promising approach is the utilization of bioinformatics in blend with systems biology and synthetic biology to recognize and deliver novel antibiotics, through mining genome & metagenome sequence information for BGCs (biosynthetic gene clusters [36]. BGC generally encodes antimicrobial molecules, like non-ribosomal peptides, polypeptide antibiotics, terpenoids, alkaloids, saccharides & bacteriocins, which mostly take part in the regulation of pathogenic microorganisms.

Two approaches that can be created more impact in this multiple drug resistance bacterial infection management are systems biology & synthetic biology as we told. Systems biology signifies to create novel processes to consider the usefulness of the living system as an entire [37]. When contemplating bacteria, these approaches not only assist to comprehend how microbes evolve, acclimatize and interrelate with other living beings but also uncover the outline & the dynamics of metabolites, proteins and RNAs. It also deciphers their

intracellular interactions &reveals the complex regulatory networks [38]. Another strategy is synthetic biology that centers on creating artificial implements to achieve specific functions. Microbes are amazing hosts for some significant purposes, for example, bioconversion, bio-production, biodegradation and bioremediation. Predominantly, the engineered microorganisms have been broadly employed to make therapeutic proteins, chemicals, enzymes, biofuels, small molecular pharmaceuticals & other materials [39]. Even though systems biology & synthetic biology spotlight respectively on science & innovation, information of systems biology conducts the propose of better-engineered science tools, which can thusly give experiences to systems biology. In this unique circumstance, drug repurposing, that consists of utilizing a non-antibiotic compound to treat MDR, is supported. Notwithstanding, it could be a great relief of using available novel antibiotics like beta lactam/beta lactamase inhibitor based and non-beta lactam based agents. To prevent the spread of infection & impending septicemia, an effective drug routine is an essential requirement. So, treatment protocol must be commenced keeping all these aspects in mind**.**

REFERENCES

1. Komura S, Kurahashi K, 1979. Partial purification and properties of L-2, 4-diaminobutyric acid activating enzyme from a polymyxin E producing organism. J. Biochem. 86(4), Pages-1013-1021.
2. Carroll LM, Gaballa A, Guldimann C, et al, 2019. Identification of novel mobilized colistin resistance gene mcr-9 in a multidrug-resistant, colistin-susceptible Salmonella enterica serotype Typhimurium isolate. M Bio. *10*(3), Pages- e00853-19.
3. Brennan-Krohn T, Pironti A, Kirby JE, 2018. Synergistic activity of colistin-containing combinations against colistin-resistant Enterobacteriaceae. Antimicrob. Agents Chemother. *62*(10), Pages- e00873-18.
4. Biswas S, Brunel JM, Dubus JC, et al, 2012. Colistin: an update on the antibiotic of the 21st century. Expert Rev Anti Infect Ther. 10(8), Pages-917-934.
5. Breazeale SD, Ribeiro AA, McClerren AL, et al, 2005. A Formyltransferase Required for Polymyxin Resistance in *Escherichia coli* and the Modification of Lipid A with 4-Amino-4-deoxy-l-arabinose identification and function of udp-4-deoxy-4-formamido-l-arabinose. J. Biol. Chem. 8; 280, Pages-14154-14167.
6. Nakajima K, 1967. Structure-activity relationship of colistins. Chem. Pharm. Bull. 25, 15(8), Pages-1219-1224.
7. Reed MD, Stern RC, O'Riordan MA, et al, 2001. The pharmacokinetics of colistin in patients with cystic fibrosis. J. Clin. Pharmacol. 41(6), Pages-645-654.
8. Ryan KJ, Schainuck LI, Hickman RO, et al, 2007. Colistimethate toxicity: report of a fatal case in a previously healthy child. Jama. 17, 207(11), Pages-2099-2101
9. Davies J, Davies D, 2010. Origins and evolution of antibiotic resistance. Microbiol Mol Biol Rev, 77, Pages-417–433.
10. Aminov RI, 2010. A brief history of the antibiotic era: lessons learned and challenges for the future. Front Microbiol 1, Page-134.
11. Tang SS, Apisarnthanarak A, Hsu LY, 2014. Mechanisms of b-lactam antimicrobial resistance and epidemiology of major community- and healthcare-associated multidrug resistant bacteria. Adv Drug Deliv Rev, 78, Pages- 3–13.
12. Fonseca JD, Knight GM, McHugh TD, 2015. The complex evolution of antibiotic resistance in Mycobacterium tuberculosis. Int J Infect Dis, 32, Pages- 94–100.
13. Deutschendorf C, Goldani LZ, Santos RP, 2012. Previous use of quinolones: a surrogate marker for first line anti-tuberculosis drugs resistance in HIV-infected patients? Braz J Infect Dis. 16, Pages- 142–145.
14. Kariuki S, Revathi G, Kiiru J, 2010 . Typhoid in Kenya is associated with a dominant multidrug-resistant Salmonella enterica serovar Typhi haplotype that is also widespread in Southeast Asia. J Clin Microbiol, 48, Pages- 2171–2176.
15. Baker S, 2015. A return to the pre-antimicrobial era? Science, 347, Pages- 1064–1066.
16. Koirala KD, Thanh DP, Thapa SD, 2012. Highly resistant Salmonella enterica serovar Typhi with a novel gyrA mutation raises questions about the long-term efficacy of older fluoroquinolones for treating typhoid fever. Antimicrob Agents Chemother. 56, Pages- 2761–2762.
17. Falagas ME, Kasiakou SK, Saravolatz LD, 2005. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin. Infect. Dis. 40(9), Pages-1333-1341.
18. Okimura K, Ohki K, Sato Y,et al, 2007. Semi-synthesis of Polymyxin B (2-10) and Colistin (2-10) analogs employing the Trichloroethoxycarbonyl (Troc) group for side chain protection of α, γ-diaminobutyric acid residues. Chem. Pharm. Bull. 55(12), Pages- 1724-1730.
19. Ledson MJ, Gallagher MJ, Cowperthwaite C, et al, 1998. Four years' experience of intravenous colomycin in an adult cystic fibrosis unit. Eur Res J. 12(3), Pages- 592-594.
20. Li J, Nation RL, Turnidge JD, et al, 2006.Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis. 6(9), Pages- 589-601.
21. Landman D, Georgescu C, Martin DA, et al, 2008. Polymyxins revisited. Clin. Microbiol. Rev. 21(3), Pages- 449-465.
22. Aquilini E, Merino S, Knirel YA, rt al, 2014. Functional identification of Proteus mirabilis eptC gene encoding a core lipopolysaccharide phosphorethanolaminetransferase. Int. J. Mol. Sci. 15(4), Pages- 6689-6702.
23. Rudan I, Chan KY, Zhang JSF, et al, 2010. On behalf of WHO/UNICEF's Child Health Epidemiology Reference Group (CHERG). Causes of deaths in children younger than 5 years in China in 2008. Lancet. 375, Pages- 1083–1089.
24. World Health Organization, 1998. Marketing authorization of pharmaceutical products with special reference to multisource (generic) products: a manual for a drug regulatory authority. Geneva.
25. Gould IM, 2008. The epidemiology of antibiotic resistance. Int J Antimicrob Agents. 32, Pages- S2–9.
26. Nugent R, Back E, Beith A, 2010. The race against drug resistance. Washington: Center for Global Development; Washington (DC), pp. 183.
27. Outterson K, Powers JH, Gould IM, et al, 2010. Questions about the 10×'20 Initiative. Clin Infect Dis 51(6), Pages-751-2.
28. Bergman M, Huikko S, Pihlajama¨ ki M, 2004. Effect of macrolide consumption on erythromycin resistance in

Streptococcus pyogenes in Finland in 1997-2001. Clin Infect Dis. 38, Pages-1251–1256.
29. Livermore DM, 2014. Of stewardship, motherhood and apple pie. Int J Antimicrob Agents. 43, Pages- 319–322.
30. Nilholm H, Holmstrand L, Ahl J, 2015. An audit-based, infectious disease specialist-guided antimicrobial stewardship program profoundly reduced antibiotic use without negatively affecting patient outcomes. Open Forum Infect Dis. 2(2), Pages-042.
31. Claret J, 2015. The world alliance against antibiotic resistance: consensus for a declaration. Clin Infect Dis. 60(12), Pages-1837–1841.
32. Morrissey I, Hackel M, Badal R, 2013. A review of ten years of study for monitoring antimicrobial resistance trends (SMART) from 2002 to 2011. Pharmaceut.6, Pages-1335–1346.
33. Falagas ME, Kasiakou SK, Saravolatz LD, 2005. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin. Infect. Dis. 40(9), Pages-1333-1341.
34. Zhou Z, Ribeiro AA, Lin S, et al, 2001. Lipid a modifications in polymyxin-resistant *Salmonella typhimurium* PmrA-dependent 4-amino-4-deoxy-l-arabinose, and phosphor ethanolamine incorporation. J. Biol. Chem. 16, 276(46), Pages-43111-43121.
35. Medema MH, Kottmann R, Yilmaz P, et al, 2015. Minimum information about a biosynthetic gene cluster. Nat. Chem. Biol. (9), Pages-625-631.
36. Navid A, Ghim CM, Fenley AT, et al, 2009. Systems biology of microbial communities. Humana Press. In Systems Biol. Pages-469-494.
37. Zaneveld JR, Parfrey LW, Van Treuren W, et al, 2011. Combined phylogenetic and genomic approaches for the high-throughput study of microbial habitat adaptation. Trends Microbiol. 19(10), Pages- 472-482.
38. Picataggio S, 2009. Potential impact of synthetic biology on the development of microbial systems for the production of renewable fuels and chemicals. Curr. Opin. Biotechnol. 20(3), Pages-325-359.
39. Gowen CM, Fong SS, 2011. Applications of systems biology towards microbial fuel production. Trends Microbiol. 19(10), Pages- 516-524.

How to cite this article

Swayamprabha Sahoo, Jatindra Nath Mohanty, Tapas Ranjan Behera, Rajesh Kumar Lenka, Saurjya Ranjan Das, 2022. Global concern of antimicrobial effectiveness and resistance Combat strategies. J. Med. P'ceutical Allied Sci. V 11 – I 3, Pages – 4827 – 4832, doi: 10.55522/jmpas.V11I3.1874.